SUV Max as Predictor of Outcome in Cervical Cancer

This study has been completed.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT01262144
First received: November 23, 2010
Last updated: December 15, 2010
Last verified: November 2010

November 23, 2010
December 15, 2010
August 2010
Not Provided
Administration of adjuvant therapy [ Time Frame: immediately following surgery ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01262144 on ClinicalTrials.gov Archive Site
Overall survival [ Time Frame: surgery - present day ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
SUV Max as Predictor of Outcome in Cervical Cancer
A Study to Evaluate the Value of SUV-Max in PET-FDG in Predicting Outcome of Surgery Vis a Vis Need for Radiotherapy

Cervical Cancer is staged clinically, not surgically. Patients in whom an extensive disease is identified are not usually eligible for surgery. PET-CT is used to support staging. However, some patients received surgery after staging and subsequently require radio/chemotherapy due to findings on operation.

This study will attempt to find a correlation between SUV-Max on PET-CT and subsequent outcomes i.e. need for adjuvant therapy.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Females age 18-80, diagnosed with cervical cancer

Cervical Cancer
Radiation: Radiotherapy
Radiotherapy for cervical cancer
Case group
Intervention: Radiation: Radiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
Not Provided
Not Provided

Inclusion Criteria:

  • having stating PET-CT stored on site
  • treated with surgery

Exclusion Criteria:

  • not eligible for surgery based on PET-CT, clinical stage
Female
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT01262144
421CTIL
No
Dr. Amit Amnon, director, gynecologic oncology unit, Rambam Health Care Campus
Rambam Health Care Campus
Not Provided
Principal Investigator: Amnon Amit, MD Rambam Health Care Campus
Rambam Health Care Campus
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP